Today
-2.11%
5 Days
-6.16%
1 Month
+4.46%
6 Months
+2.18%
Year to Date
-11.81%
1 Year
0.00%
• Proposed CMS oversight initiatives create uncertainty around long-term margin stability. • Vertical integration scrutiny increases operational risk for UnitedHealth Group. • Elevated medical utilization and cost trends compress managed care underwriting spreads.
• Institutional profit-taking and technical mean reversion drove Medline shares lower. • Regulatory safety notices and manufacturing remediation expenses weighed on sentiment. • Gross margin contraction resulted from inventory inflation and elevated distribution expenses.
• Medline's stock rallied due to bargain-hunting and positive executive presentations at conferences. • The company reported annual revenue of $28.43B and a net profit of $1.16B. • Analysts issued Buy ratings with an average price target of $44.52.
Medline (MDLN) Q3 2026 Earnings Call: Sales Guidance Raised, 2027 Margin Pressure Ahead


| Shareholders | Proportion |
|---|---|
| The Carlyle Group | 22.12% |
| Blackstone Inc. | 14.69% |
| GIC Private Limited | 14.05% |
| Hellman & Friedman LLC | 10.23% |
| Shareholder Types | Proportion |
|---|---|
| Private Equity | 48.66% |
| Sovereign Wealth Fund | 20.31% |
| Investment Advisor | 16.67% |
| Investment Advisor/Hedge Fund | 8.43% |
Related Instruments